A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Constellation Pharmaceuticals
Constellation Pharmaceuticals
Ohio State University Comprehensive Cancer Center
Novartis
Children's Oncology Group